Is pindolol augmentation effective in depressed patients resistant to selective serotonin reuptake inhibitors? A systematic review and meta‐analysis

  title={Is pindolol augmentation effective in depressed patients resistant to selective serotonin reuptake inhibitors? A systematic review and meta‐analysis},
  author={Yiyun Liu and Xinyu Zhou and Dan Zhu and Jian-jun Chen and B. Qin and Yuqing Zhang and Xiao Wang and Deyu Yang and Hua-qing Meng and Qing-hua Luo and Peng Xie},
  journal={Human Psychopharmacology: Clinical and Experimental},
  pages={132 - 142}
  • Yiyun Liu, Xinyu Zhou, P. Xie
  • Published 1 May 2015
  • Psychology, Medicine
  • Human Psychopharmacology: Clinical and Experimental
This systematic review and meta‐analysis was conducted to assess the use of pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitor (SSRI) therapy. 

β‐Blocker–Induced Tremor

2 patients with tremor induced or worsened by β‐blockers with partial β‐agonist activity on β‐adrenoreceptors are reported.

The Use of β-Adrenergic Receptor Antagonists in Psychiatry: A Review.

Adjuvant Therapy With β-Adrenergic Blockers in Psychiatry

The clinical use of b-blockers in such diverse indications while examining the extant evidence is brief, and cautious interpretation is then highly warranted.

Neuropsychiatric Consequences of Lipophilic Beta-Blockers

The relationship between beta-blockers and the central nervous system appears as a two-sided coin and it is suggested that clinicians pay special attention to the pharmacological properties of different beta- blockers.

Treatment-Resistant Depression

  • C. CusinStefan Peyda
  • Psychology, Medicine
    The Massachusetts General Hospital Guide to Depression
  • 2018
This chapter presents an overview of this complex clinical problem, including epidemiology and challenges with definition and classification of TRD, and steps for its treatment, including optimization, augmentation, and combination of pharmacologic agents.

Pharmacological interventions for treatment-resistant depression in adults.

There was no evidence of a difference in depression severity when current treatment was switched to mianserin, and eight studies augmented current antidepressant treatment with a non-antidepressant or an antipsychotic (cariprazine; olanzapine; quetiapine); or ziprasidone (2 studies).

Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births

The evidence suggests a generally small risk of congenital malformations and argues against a substantial teratogenic effect of SSRIs and Caution is advisable in making decisions about whether to continue or stop treatment withSSRIs during pregnancy.

Definition of treatment-resistant depression - Asia Pacific perspectives.

Antihypertensive Drugs and Risk of Depression

Real-life population-based data suggest a positive effect of continued use of 9 individual antihypertensive agents should be used in guiding prescriptions for patients at risk of developing depression including those with prior depression or anxiety and patients with a family history of depression.



Pindolol augmentation of sertraline in resistant depression and its effect on sleep

A case is reported of a 34-year-old lady with a 2-year history of resistant depression who responded to pindolol augmentation of sertraline. It also illustrates the use of sleep electroencephalogram

Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.

A double-blind, randomized, controlled 6-week study of pindolol augmentation of selective serotonin reuptake inhibitors (SSRIs) in depressed outpatients resistant to SSRI monotherapy finds that the efficacy of pINDolol in augmenting clinical response to SSRIs in treatment-resistant depressed patients is not supported.

Potentiation strategies for treatment‐resistant depression

The pharmacological basis of antidepressant potentiation in combination therapy and the clinical evidence for its efficacy are reviewed.

Pindolol augmentation of selective serotonin reuptake inhibitors: Accounting for the variability of results of placebo‐controlled double‐blind studies in patients with major depression

The present review briefly presents the results of placebo‐controlled double‐blind trials of pindolol augmentation of SSRIs in patients with major depression, and focuses on factors that may account for the variability of findings.

Rapid cycling triggered by pindolol augmentation of paroxetine, but not with desipramine.

A treatment-resistant depressed patient developed bipolar rapid cycling in response to pindolol augmentation of paroxetine, after failing to respond in any fashion to pindolol added to desipramine.

Pindolol augmentation of treatment-resistant depressed patients.

This study failed to replicate the rapid and dramatic response to pindolol augmentation in treatment-resistant depressed patients.

Pindolol augmentation of antidepressant therapy

Open-label studies strongly suggest that pindolol may accelerate and augment antidepressant response, but controlled studies do not wholly support these findings: only three of six studies clearly demonstrate benefit.

Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression.

The results of these studies indicate that pindolol is safe when used in combination with an SSRI or moclobemide and should be tested under double-blind conditions to establish its efficacy.